Illumina Inc (ILMN) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumab...
Illumina Inc's revenue decreased 0.7% year over year, from $4.37B to $4.34B.
Net income increased 169.5% over the same period, from $-1.22B to $850.0M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 81% in total.
Total debt remained relatively stable at $2.55B.
The debt-to-equity ratio stands at 0.94, indicating a moderate leverage profile.
Operating cash flow grew 28.9% to $1.08B.
Illumina Inc maintains a healthy net profit margin of 19.6%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $1.08B-2.9% | $705.0M | $855.0M | $1.88B | $316.0M | $6.01B | $2.67B | $2.13B |
| Q4 FY2024 | $1.10B+2.2% | $186.0M | $618.0M | $267.0M | $364.0M | $6.30B | $2.62B | $2.37B |
| Q1 FY2025 | $1.04B-5.7% | $131.0M | $683.0M | $164.0M | $240.0M | $6.18B | N/A | $2.37B |
| Q2 FY2025 | $1.06B+1.7% | $235.0M | $695.0M | $214.0M | $234.0M | $6.09B | N/A | $2.26B |
| Q3 FY2025 | $1.08B+2.4% | $150.0M | $733.0M | $228.0M | $284.0M | $6.18B | N/A | $2.38B |
| Q4 FY2025 | $1.16B+6.9% | $334.0M | $759.0M | $201.0M | $321.0M | $6.64B | $2.55B | $2.72B |
| Q1 FY2026 | $1.09B-5.9% | $134.0M | $721.0M | $209.0M | $289.0M | N/A | N/A | N/A |
| Q2 FY2026 | $1.16B+6.3% | $206.0M | $770.0M | $245.0M | $201.0M | N/A | N/A | N/A |
Balance Sheet Summary (FY2025)
Illumina Inc (ILMN) Financial Statements & Revenue History
Illumina Inc (ILMN) is a US-listed stock operating in the Technology sector, specifically the Laboratory Analytical Instruments industry trading at $258.01 with a market capitalization of $39. This page provides 42 historical financial statements for Illumina Inc, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Illumina Inc reported revenue of $4.3 billion, a 0.7% decline from the prior year. The net profit margin of 19.6% reflects strong profitability. The debt-to-equity ratio of 0.94 reflects moderate leverage.
ILMN Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Illumina Inc's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether ILMN is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track ILMN's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Illumina Inc converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of ILMN's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use ILMN Financial Data
Investors use Illumina Inc's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare ILMN's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how ILMN's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View ILMN's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Illumina Inc's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.ILMN trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.